

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent of **Abramovici et al.**

U.S. Patent No.: **7,323,493**

Issued: **January 29, 2008**

Title: **Solid Pharmaceutical Compositions Containing Benzofuran Derivatives**

**REQUEST FOR CERTIFICATE OF CORRECTION FOR PTO MISTAKE**  
**UNDER 35 U.S.C. 254 and 37 C.F.R. 1.322**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450  
**Attn: Certificate of Correction Branch**

In the matter of U.S. Patent No. 7,323,493, it is respectfully requested that a Certificate of Correction be issued to cover the following errors which occurred in the printing of the patent:

1. Column 4, line 37 (page 7, line 24 of the Specification): "Na<sub>2</sub> HPO<sub>4</sub>" should read as --Na<sub>2</sub>HPO<sub>4</sub> --.
2. Column 4, line 42 (page 8, line 1 of the Specification): Please insert the following text: --The following results were thus obtained: -- .

Support for the correction of the following errors can be found in the Amendment filed on January 12, 2007, as acknowledged by the Examiner in the Notice of Allowability and Interview Summary (PTOL-413) dated September 19, 2007:

3. Column 1, line 1: Insert the following text: --Cross Reference to Related Applications --.

4. Column 1, line 2: Insert the following text: --This application is a 35 U.S.C. § 371 application of PCT International Application No. PCT/FR98/01285 filed June 19, 1998. --.
5. Claim 3, column 10, line 29 (see claim 2 of Amendment filed January 12, 2007):  
"claim 2" should read as -- claim 1 --.
6. Claim 4, column 10, line 32 (see claim 3 of Amendment filed January 12, 2007):  
"claim 2" should read as -- claim 1 --.
7. Claim 12, column 10, line 59 (see claim 20 of Amendment filed January 12, 2007):  
Cancel the following text: "or a pharmaceutically acceptable salt thereof".

**REMARKS**

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent. All of the above errors occurred during the printing of the patent and, therefore, no fee is due. However, the Commissioner is hereby authorized to charge any fees that are required by this paper to Deposit Account No. 18-1982.

A copy of the required Certificate of Correction Form PTO-1050 is enclosed.

Respectfully submitted,

March 17, 2008  
Date

Kelly L. Bender  
Kelly L. Bender, Registry No. 52,610  
Attorney for Applicant

sanofi-aventis U.S. Inc.  
U.S. Patent Operations  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (610) 889-8995  
Telefax (908) 231-2626

sanofi-aventis Docket No. IVD000994 US PCT

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,323,493

DATED : January 29, 2008

INVENTOR(s) : Abramovici et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1, line 1: Insert the following text: --Cross Reference to Related Applications --.

Column 1, line 2: Insert the following text: --This application is a 35 U.S.C. § 371 application of PCT International Application No. PCT/FR98/01285 filed June 19, 1998. --.

Column 4, line 37: "Na<sub>2</sub> HPO<sub>4</sub>" should read as --Na<sub>2</sub>HPO<sub>4</sub> --;

Column 4, line 42: Insert the following text: --The following results were thus obtained: -- .

Claim 3, line 29: "claim 2" should read as -- claim 1 --.

Claim 4, line 32: "claim 2" should read as -- claim 1 --.

Claim 12, line 59: Cancel the following text: "or a pharmaceutically acceptable salt thereof".

Mailing Address of Sender:

Patent No. 7,323,493

Kelly L. Bender, U.S. Patent Operations  
sanofi-aventis U.S. Inc.  
Route #202-206  
P. O. Box 6800  
Bridgewater, New Jersey 08807-0800

⇒ 1 of 1

Certificate of Correction (PTO Form 1050) - Amended